Stifel Nicolaus Keeps Their Hold Rating on Ventyx Biosciences (VTYX)

Stifel Nicolaus analyst Alex Thompson CFA maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) on May 14 and set a price target of $6.00. The company’s shares closed yesterday at $4.19.

According to TipRanks, Thompson CFA is a 4-star analyst with an average return of 15.9% and a 47.27% success rate. Thompson CFA covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Argenx Se, and Pliant Therapeutics.

Currently, the analyst consensus on Ventyx Biosciences is a Strong Buy with an average price target of $11.57, a 176.13% upside from current levels. In a report released on May 10, H.C. Wainwright also maintained a Hold rating on the stock with a $6.00 price target.

VTYX market cap is currently $294M and has a P/E ratio of -1.29.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VTYX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ventyx Biosciences (VTYX) Company Description:

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.